• [Article] NA Vaccine Institute Acquires World Class Product Certification for Immune Enhancer 'Nexavant'

  2024-11-20

   NA Vaccine Institute announced today that Nexavant, an immune enhancer developed by the company, has been selected as a “Next Generation World Class Product” in the “World Class Product” certification program organized by KOTRA, the Korea Trade-Inve…

  View More →

• [Article] NA Vaccine Institue and Harvard Medical School's MGH Collaborate on Immuno-Oncancer Drug Development

  2024-11-20

   A domestic vaccine development company, NA Vaccine Institute, has joined hands with Harvard Medical School and Massachusetts General Hospital (MGH) to develop immuno-oncology drugs. On the 7th, the company announced that it has signed a memorandum o…

  View More →

• [Article] NA Vaccine Institute confirms high anti-cancer effect based on ‘Nexavant’

  2024-07-10

  NA Vaccine Institute (CEO Kim Dong-ho), a company that develops vaccines to prevent and treat infectious diseases and incurable cancers, published a paper confirming the mechanism and effects of an innovative anti-cancer treatment based on Nexavant, …

  View More →

• [Article] NA Vaccine Institute selected for national new drug development project for malignant brain tumor treatment vaccine

  2024-07-10

  The NA Vaccine Institute announced on the 20th that its glioblastoma treatment vaccine development project was selected for this year's first national new drug development project of the National New Drug Development Foundation. Through this project,…

  View More →

• [Article] NA Vaccine Institute publishes results of superiority of self-developed immune booster ‘Nexavant’ in international academic journal

  2024-07-04

  NA Vaccine Institute (CEO Kim Dong-ho) announced on the 27th that it has proven that 'Nexavant', a new RNA-based immune enhancer developed in-house, can be an excellent immune enhancer as a result of joint research with Professor Han Seung-hyun's tea…

  View More →

• [Article] NA Vaccine Institute selected as a global vaccine technology leader for flu and peptide tuberculosis vaccines

  2024-07-04

  NA Vaccine Institute, a vaccine development company, announced on the 26th that the influenza vaccine and peptide tuberculosis vaccine using its self-developed mucosal immunity enhancer platform were selected for the first new project hosted by the G…

  View More →

• [Article] “An anti-cancer vaccine challenge with Japan’s National Cancer Center using the Nexavac platform”

  2023-11-29

  Interview | Dongho Kim, CEO of NA Vaccine Institute“(Japan’s National Cancer Center) agreed that the difficulties they had in clinical development could be solved through our Nexavac platform, so the collaboration took place.”On the 1st, the NA Vacci…

  View More →

• [Article] Eutilex signs MOU with NA Vaccine Institute

  2023-11-29

  Eutilex CEO Choi Soo-young (third from the right), NA Vaccine Research Institute CEO Kim Dong-ho (third from the left) and other officials are taking a commemorative photo after the MOU. (Provided by Eutilex) [Edaily Reporter Kim Ji-wan] Eutilex anno…

  View More →

• [Interview] Dong-ho Kim, CEO of NA Vaccine Institute, “Spurring the development of the world’s first nasal inhalation vaccine”

  2023-11-29

  "The goal is to develop a vaccine that can be easily used by people in third world countries and benefit them. Our vaccine candidate can be self-administered does not require refrigeration and  because it is sprayed into the nose." These are the word…

  View More →